Lakewood-Amedex Biotherapeutics has announced encouraging antimicrobial resistance (AMR) data for its lead investigational compound Nu-3, being developed as a topical treatment for infected Diabetic Foot Ulcers (iDFU). The findings highlight the compound’s potential to address the growing challenge of antibiotic resistance.

Nu-3 belongs to the company’s proprietary Bisphosphocin® class of antimicrobial compounds, a novel category designed to deliver rapid and broad-spectrum activity against bacterial infections. In laboratory studies, these compounds demonstrated the ability to kill bacteria within minutes by destabilising bacterial cell membranes in a pH- and concentration-dependent manner.

The research showed that Nu-3 maintained strong antimicrobial activity even after prolonged exposure. In a 21-day serial passage study involving bacteria such as E. coli and Methicillin-resistant Staphylococcus aureus, the compound exhibited minimal changes in its minimum inhibitory concentration (MIC), indicating low resistance development. In contrast, the comparator antibiotic Ciprofloxacin showed a dramatic increase in resistance levels, with MIC rising more than 2,000-fold for E. coli and over 600-fold for MRSA.

Importantly, Nu-3 also retained its effectiveness against bacteria that had already developed resistance to Ciprofloxacin, suggesting no cross-resistance—an advantage that could position it as a valuable tool in combating multidrug-resistant infections.

The company noted that antimicrobial resistance remains a major global health concern, contributing to approximately 1.27 million deaths annually and playing a role in nearly 5 million deaths worldwide. The need for new and effective treatments is particularly urgent in conditions such as diabetic foot ulcers, where infections can lead to severe complications.

Globally, a significant proportion of individuals with diabetes develop foot ulcers during their lifetime, and nearly half of these cases become infected. Resistant pathogens, particularly MRSA, account for 15–20 percent of infected cases, increasing the risk of complications such as amputations if not treated effectively.

Nu-3 is being developed to address this unmet medical need by offering a fast-acting, topical solution capable of targeting both gram-positive and gram-negative bacteria, including multidrug-resistant strains. The company is also exploring the broader application of the Bisphosphocin class in treating other infections, such as complicated urinary tract infections and pulmonary diseases.

With its unique mechanism of action and strong resistance profile, Nu-3 represents a promising advancement in the fight against antimicrobial resistance and could significantly improve outcomes for patients with difficult-to-treat infections.